Karyopharm Therapeutics Inc. Common Stock
KPTIUnited States
5 filed reports · 233 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 738 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 690 | Dec 2025 |
Financial data
233 concepts · 1,428 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial228 concepts · 1,354 facts · Dec 2023 to Jun 2026
- Ending balance24 · Dec 2023 to Dec 2025
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Allocated share based compensation expense13 · Dec 2023 to Jun 2026
- Cash and cash equivalents at carrying value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Restricted cash and cash equivalents noncurrent13 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Deferred royalty obligation12 · Dec 2024 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Nonoperating income expense12 · Dec 2023 to Jun 2026
- Operating expenses (US GAAP)12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Other comprehensive income loss foreign currency transaction and translation adjustment net of tax12 · Dec 2023 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax12 · Dec 2023 to Jun 2026
- Other nonoperating income expense12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
- Total license and other revenue12 · Dec 2023 to Jun 2026
- Accretion amortization of discounts and premiums investments11 · Dec 2023 to Jun 2026
Product5 concepts · 74 facts · Dec 2023 to Jun 2026
- Cost of goods and services sold (US GAAP)24 · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
- Total license and other revenue12 · Dec 2023 to Jun 2026
- Gross product revenue7 · Jun 2024 to Jun 2026
- Provisions for product revenue7 · Jun 2024 to Jun 2026
Segments
74 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service3 members · 74 facts
- Product50 · Dec 2023 to Jun 2026
- Health Care Other12 · Dec 2023 to Jun 2026
- License And Other12 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 13, 2026
- FY2026 Q1May 14, 2026
- FY2025 Q4Feb 12, 2026
- FY2025 Q3Nov 3, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.